DK1506287T3 - Fremgangsmåder til oprensning af adenovirus - Google Patents

Fremgangsmåder til oprensning af adenovirus

Info

Publication number
DK1506287T3
DK1506287T3 DK03726841T DK03726841T DK1506287T3 DK 1506287 T3 DK1506287 T3 DK 1506287T3 DK 03726841 T DK03726841 T DK 03726841T DK 03726841 T DK03726841 T DK 03726841T DK 1506287 T3 DK1506287 T3 DK 1506287T3
Authority
DK
Denmark
Prior art keywords
methods
virus
purifying
particles
levels
Prior art date
Application number
DK03726841T
Other languages
Danish (da)
English (en)
Inventor
Aaron R Goerke
Chi Shung Brian To
John O Konz Jr
Ann L Lee
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29549953&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1506287(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DK1506287T3 publication Critical patent/DK1506287T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
DK03726841T 2002-05-14 2003-05-13 Fremgangsmåder til oprensning af adenovirus DK1506287T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38033202P 2002-05-14 2002-05-14
PCT/US2003/015061 WO2003097797A2 (en) 2002-05-14 2003-05-13 Methods of adenovirus purification

Publications (1)

Publication Number Publication Date
DK1506287T3 true DK1506287T3 (da) 2007-08-20

Family

ID=29549953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03726841T DK1506287T3 (da) 2002-05-14 2003-05-13 Fremgangsmåder til oprensning af adenovirus

Country Status (9)

Country Link
US (3) US20050196854A1 (de)
EP (2) EP1506287B1 (de)
AT (2) ATE360683T1 (de)
AU (1) AU2003229060A1 (de)
DE (2) DE60313451T2 (de)
DK (1) DK1506287T3 (de)
ES (2) ES2285120T3 (de)
PT (1) PT1506287E (de)
WO (1) WO2003097797A2 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
ES2329607T3 (es) * 2004-02-23 2009-11-27 Crucell Holland B.V. Metodos de purificacion de virus.
BRPI0511764B8 (pt) * 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
CA2586107A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
WO2006086284A2 (en) * 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
US7673757B2 (en) 2006-02-17 2010-03-09 Millipore Corporation Adsorbent filter media for removal of biological contaminants in process liquids
ATE539149T1 (de) * 2006-04-20 2012-01-15 Wyeth Llc Reinigungsverfahren zur isolierung von gereinigtem vesikulärem stomatitisvirus aus zellkultur
DE602008006410D1 (de) * 2007-06-15 2011-06-01 Amgen Inc Verfahren zur behandlung von zellkulturmedien für die verwendung in einem bioreaktor
WO2009153563A1 (en) 2008-06-18 2009-12-23 Oxford Biomedica (Uk) Limited Virus purification
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
JP2010207800A (ja) * 2009-02-16 2010-09-24 Kuraray Co Ltd ろ過ユニットおよびこれを備えたろ過装置
CN102575233B (zh) * 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
PL2488636T3 (pl) * 2009-10-15 2014-07-31 Crucell Holland Bv Sposób oczyszczania cząsteczek adenowirusów z hodowli o wysokim zagęszczeniu komórkowym
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
WO2012010280A1 (en) 2010-07-20 2012-01-26 Bavarian Nordic A/S Method for harvesting expression products
TWI503411B (zh) * 2010-08-11 2015-10-11 Nat Health Research Institutes Ｂ群腦膜炎球菌次單位疫苗之製造及純化
DE102010046817A1 (de) * 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
MY169352A (en) 2012-03-22 2019-03-25 Janssen Vaccines & Prevention Bv Vaccine against rsv
CN104884933B (zh) * 2012-10-18 2019-03-01 伊诺瓦普瑞普有限公司 液体向液体的生物粒子分级和浓缩
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
WO2015052177A1 (en) * 2013-10-07 2015-04-16 Novartis Ag Treated filter
WO2015120447A1 (en) * 2014-02-10 2015-08-13 Zymo Research Corporation Methods of nucleic acid capture
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
US10023846B2 (en) 2014-07-10 2018-07-17 Takara Bio Inc. Production method for non-enveloped virus particles
DK3172317T3 (da) 2014-07-24 2019-07-22 Janssen Vaccines & Prevention Bv Fremgangsmåde til oprensning af poliovirus fra cellekulturer
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
IL292999A (en) 2014-11-14 2022-07-01 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
CN107109374B (zh) * 2015-01-09 2021-04-06 宝生物工程株式会社 用于生产无包膜病毒颗粒的方法
CN107428799A (zh) 2015-01-13 2017-12-01 阿尔法韦士曼公司 纯化腺相关病毒(AAV)及/或重组腺相关病毒(rAAV)之方法及其梯度和流通式缓冲液
EP3054007A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten, adeno-assoziierten viren mit einem immunaffinen reinigungsschritt
EP3054006A1 (de) 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Reinigung von rekombinanten adeno-assoziierten viruspartikeln mittels mehrstufiger anionischer austauschchromatografie
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
KR102500970B1 (ko) 2016-04-05 2023-02-17 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7046835B2 (ja) 2016-05-12 2022-04-04 ヤンセン ファッシンズ アンド プリベンション ベーフェー 強力でバランスのとれた双方向性プロモーター
SG11201809699XA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Modulatory polynucleotides
KR20220108216A (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN109312362B (zh) 2016-06-20 2022-06-28 扬森疫苗与预防公司 有效和平衡的双向启动子
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
KR20190045174A (ko) 2016-07-21 2019-05-02 스파크 테라퓨틱스, 인코포레이티드 재조합 아데노신 관련 바이러스(rAAV) 벡터를 고수율로 생산하기 위한 확장 가능한 고회수 방법 및 이에 의해 생산된 재조합 아데노-관련 바이러스(rAAV) 벡터
CN110650673B (zh) 2016-08-30 2024-04-09 加利福尼亚大学董事会 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统
CN110168081B (zh) * 2016-11-04 2024-08-16 武田药品工业株式会社 腺相关病毒纯化方法
CN108085301B (zh) * 2016-11-22 2021-10-26 贺道耀 从宿主细胞提取和纯化腺相关病毒和腺病毒的方法及其组分和试剂盒
US10294452B2 (en) 2016-11-22 2019-05-21 Dao-Yao He Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells
SG11201906271QA (en) 2017-02-09 2019-08-27 Janssen Vaccines & Prevention Bv Potent and short promoter for expression of heterologous genes
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
SG11201909870SA (en) 2017-05-05 2019-11-28 Voyager Therapeutics Inc Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
US11229695B2 (en) 2017-09-15 2022-01-25 Janssen Vaccines & Prevention B.V. Method for the safe induction of immunity against RSV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
US11434502B2 (en) 2017-10-16 2022-09-06 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (ALS)
EP4454654A3 (de) 2017-10-16 2025-02-19 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose (als)
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
US20210010028A1 (en) 2018-03-06 2021-01-14 Voyager Therapeutics, Inc. Insect cell manufactured partial self-complementary aav genomes
JP7048889B2 (ja) * 2018-04-16 2022-04-06 日本電信電話株式会社 バクテリア産生セルロースカーボンの製造方法
EP3784276A4 (de) 2018-04-24 2022-03-16 Merck Sharp & Dohme Corp. Skalierbares chromatographieverfahren zur reinigung von menschlichem cytomegalovirus
US12365865B2 (en) 2018-04-29 2025-07-22 Regenxbio Inc. Scalable clarification process for recombinant AAV production
MX2020012295A (es) 2018-05-15 2021-03-31 Flagship Pioneering Innovations V Inc Composiciones de fusosoma y usos de estas.
EP3794126A1 (de) 2018-05-15 2021-03-24 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus parkinson
EP3793686A1 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Aav-serotypen zur gehirnspezifischen payload-übertragung
EP3793615A2 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
CA3103963A1 (en) 2018-07-02 2020-01-09 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
WO2020014209A1 (en) 2018-07-09 2020-01-16 Flagship Pioneering Innovations V, Inc. Fusosome compositions and uses thereof
JP2021530548A (ja) 2018-07-24 2021-11-11 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics, Inc. 遺伝子治療製剤を生産するための系および方法
CN113383010B (zh) 2018-09-28 2025-09-09 沃雅戈治疗公司 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
TW202035689A (zh) 2018-10-04 2020-10-01 美商航海家醫療公司 測量病毒載體粒子的效價及強度之方法
CN113164583A (zh) 2018-11-13 2021-07-23 扬森疫苗与预防公司 稳定的融合前rsv f蛋白
CA3120082A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for cns delivery
WO2020102485A1 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for hematopoietic stem cell delivery
WO2020102503A2 (en) 2018-11-14 2020-05-22 Flagship Pioneering Innovations V, Inc. Fusosome compositions for t cell delivery
MX2021008542A (es) 2019-01-18 2021-11-12 Voyager Therapeutics Inc Métodos y sistemas para la producción de partículas de aav.
WO2020223274A1 (en) 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
GB201909081D0 (en) * 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN111394390A (zh) * 2020-03-26 2020-07-10 赛诺（深圳）生物医药研究有限公司 用于新型冠状病毒基因疫苗的批量生产重组腺病毒的方法
EP3919613B1 (de) * 2020-06-05 2024-08-07 Sartorius BIA Separations d.o.o. Verbesserte reinigung von adeno-assoziiertem virus um kontaminierende dna effektiver zu entfernen
WO2022032153A1 (en) 2020-08-06 2022-02-10 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
RU2745307C1 (ru) * 2020-12-01 2021-03-23 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ очистки рекомбинантного аденовируса 26 серотипа (Ad26)
TW202237164A (zh) * 2020-12-04 2022-10-01 美商磨石生物公司 組合物及其使用方法
AR124306A1 (es) * 2020-12-10 2023-03-15 Astrazeneca Uk Ltd Métodos de purificación de adenovirus
AU2021404926A1 (en) * 2020-12-21 2023-07-06 Pfizer Inc. Methods and compositions for inhibiting excess nucleic acid precipitation
EP4301768A2 (de) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Kontrollierte expression von viralen proteinen
US20240141378A1 (en) 2021-03-03 2024-05-02 Voyager Therapeutics, Inc. Controlled expression of viral proteins
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
US20260085328A1 (en) 2022-09-08 2026-03-26 Voyager Therapeutics, Inc. Controlled expression of viral proteins
CN115747017B (zh) * 2022-10-25 2023-06-09 上海华新生物高技术有限公司 一种腺病毒纯化装置
AU2024251690A1 (en) * 2023-04-03 2025-11-13 Genzyme Corporation Devices for cell lysis and methods of use thereof
WO2024259672A1 (zh) * 2023-06-21 2024-12-26 上海金珂博生物技术有限公司 一种去除腺相关病毒载体颗粒中空载体颗粒的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4064232A (en) * 1974-01-14 1977-12-20 Sandoz Ltd. Process for isolating the immunogenic components of influenza viruses
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
JP4223550B2 (ja) * 1996-02-29 2009-02-12 タカラバイオ株式会社 ウイルスの精製および除去方法
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
WO2001002607A1 (en) 1999-07-06 2001-01-11 Merck & Co., Inc. Adenovirus carrying gag gene hiv vaccine
CA2799545A1 (en) 2000-03-07 2001-09-13 Merck Sharp & Dohme Corp. Adenovirus formulations
AU2001285263A1 (en) * 2000-08-25 2002-03-13 The General Hospital Corporation Selective precipitation of viruses
AU2001294562B2 (en) 2000-09-15 2007-05-24 Merck & Co., Inc. Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus

Also Published As

Publication number Publication date
ES2357366T3 (es) 2011-04-25
DE60335672D1 (de) 2011-02-17
US20050153420A1 (en) 2005-07-14
ATE494362T1 (de) 2011-01-15
DE60313451T2 (de) 2008-01-03
US7326555B2 (en) 2008-02-05
WO2003097797A2 (en) 2003-11-27
AU2003229060A1 (en) 2003-12-02
EP1783212A1 (de) 2007-05-09
EP1506287A4 (de) 2005-06-08
WO2003097797A3 (en) 2004-02-19
EP1506287B1 (de) 2007-04-25
US20080118970A1 (en) 2008-05-22
DE60313451D1 (de) 2007-06-06
ATE360683T1 (de) 2007-05-15
AU2003229060A8 (en) 2003-12-02
ES2285120T3 (es) 2007-11-16
EP1506287A2 (de) 2005-02-16
EP1783212B1 (de) 2011-01-05
PT1506287E (pt) 2007-07-17
US20050196854A1 (en) 2005-09-08

Similar Documents

Publication Publication Date Title
ATE360683T1 (de) Verfahren zur reinigung von adenovirus
ATE346861T1 (de) Verfahren zur reinigung und isolierung von viren, aus pflanzenquellen
ATE377444T1 (de) Verfahren zur reduktion von mitgerissenen feststoffen und flüssigkeiten
AR061699A1 (es) Resinas de amino - aldehido modificadas y usos de las mismas en procesos de separacion
ATE491790T1 (de) Isolierung und reinigung von nucleinsäuren
EP1961826A3 (de) Verfahren zur direkten Sequenzierung von Nukleinsäuren
WO2009052102A3 (en) Solids removal system and method
BR0114438A (pt) Processo e aparelho para o tratamento de água de despejo
DE69904986D1 (de) Methode zur Abtrennung und Wiedergewinnung von Polyethylenglykol und Siliziumkarbid-Schleifmittel zum Zwecke ihrer Wiederverwendung
WO2006071673A3 (en) Amine-aldehyde resins and uses thereof in separation processes
WO2001048155A3 (en) Method using filtration aids for the separation of virus vectors from nucleic acids and other cellular contaminants
SE8402861D0 (sv) Rening av biologiskt material
EA201270557A1 (ru) Способ очистки аденовируса из культур с высокой плотностью клеток
WO2002026617A3 (en) Process for extracting and purifying naturally occurring zeolite
DE60042343D1 (de) Abtrennung von fibrinogen von plasmaproteasen
ATE175206T1 (de) Enzymatisches reinigungsverfahren
HK1042116A1 (zh) 淨化或隔離過濾病毒核酸的方法
ATE328102T1 (de) Verfahren zur herstellung von proteine
EP1245674A3 (de) Nukleinsäurereinigung
ATE492515T1 (de) Verfahren und vorrichtung zur reinigung von luft und wasser
EP1534404A4 (de) Verwendung eines clathratmodifizierers zur forderung des durchgangs von proteinen bei nanofiltration
ATE410517T1 (de) Mittel und verfahren zur expression von homologen und heterologen proteinen in rhodococcus
BR9807061A (pt) Purificação de dna em uma centrìfuga de fluxo contìnuo
ATE492635T1 (de) Verfahren und anlage zur produktion und aufreinigung von fermentationsprodukten
ATE329046T1 (de) Parvovirus-vektoren und deren verwendung